German drug maker Merck KGaA said Wednesday that key new cancer drug won't get to market in Europe until the first half of 2009 after United States regulators rejected studies by United States developer Imclone.
German drug maker Merck delays new cancer treatment in Europe after United States regulators rejected studies.